Brokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) PT at $106.08

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) have received a consensus recommendation of “Hold” from the fifteen analysts that are presently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $106.23.

ITCI has been the topic of several recent research reports. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. StockNews.com started coverage on Intra-Cellular Therapies in a research report on Saturday. They set a “hold” rating on the stock. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $140.00 to $132.00 in a report on Monday, February 24th. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.87 on Friday. The firm’s 50-day moving average is $129.62 and its two-hundred day moving average is $101.61. The company has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies has a 52 week low of $64.09 and a 52 week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. On average, equities research analysts predict that Intra-Cellular Therapies will post -0.64 earnings per share for the current year.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB increased its stake in shares of Intra-Cellular Therapies by 124.3% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 133 shares during the last quarter. M&T Bank Corp grew its stake in Intra-Cellular Therapies by 2.2% in the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock valued at $526,000 after purchasing an additional 138 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Intra-Cellular Therapies by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 141 shares during the last quarter. CIBC Asset Management Inc raised its stake in shares of Intra-Cellular Therapies by 5.3% during the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 150 shares in the last quarter. Finally, Pallas Capital Advisors LLC lifted its holdings in shares of Intra-Cellular Therapies by 6.4% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 192 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.